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Aims EMPEROR-Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure with
preserved ejection fraction (HFpEF). This report describes the baseline characteristics of the EMPEROR-Preserved
cohort and compares them with patients enrolled in prior HFpEF trials.
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Methods
and results
EMPEROR-Preserved is a phase III randomized, international, double-blind, parallel-group, placebo-controlled trial
in which 5988 symptomatic HFpEF patients [left ventricular ejection fraction (LVEF) >40%] with and without type
2 diabetes mellitus (T2DM) have been enrolled. Patients were required to have elevated N-terminal pro B-type
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natriuretic peptide (NT-proBNP) concentrations (i.e. >300 pg/mL in patients without and >900 pg/mL in patients
with atrial fibrillation) along with evidence of structural changes in the heart or documented history of heart failure
hospitalization. Among patients enrolled from various regions (45% Europe, 11% Asia, 25% Latin America, 12% North
America), the mean age was 72± 9 years, 45% were women. Almost all patients had New York Heart Association class
II or III symptoms (99.6%), and 23% had prior heart failure hospitalization within 12 months. Thirty-three percent of
the patients had baseline LVEF of 41–50%. The mean LVEF (54± 9%) was slightly lower while the median NT-proBNP
[974 (499–1731) pg/mL] was higher compared with previous HFpEF trials. Presence of comorbidities such as diabetes
(49%) and chronic kidney disease (50%) were common. The majority of the patients were on angiotensin-converting
enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor–neprilysin inhibitors (80%) and beta-blockers
(86%), and 37% of patients were on mineralocorticoid receptor antagonists.
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Conclusion When compared with prior trials in HFpEF, the EMPEROR-Preserved cohort has a somewhat higher burden of
comorbidities, lower LVEF, higher median NT-proBNP and greater use of mineralocorticoid receptor antagonists at
baseline. Results of the EMPEROR-Preserved trial will be available in 2021.
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Keywords Heart failure with preserved ejection fraction • Sodium–glucose co-transporter 2 inhibitors •
Empagliflozin
Introduction
Heart failure (HF) with preserved ejection fraction (HFpEF) affects
many million patients globally and is associated with substantial
morbidity and mortality for patients and cost to society.1 There
are no therapies that are approved to reduce HF hospitalizations
or mortality in HFpEF patients.2–4 In addition to being at high
risk of mortality and morbidity, HFpEF patients also often have
impaired quality of life and functional capacity, which is comparable
to patients living with end-stage renal disease.5 The mechanistic
pathways to develop successful novel therapeutics in HFpEF are
still being explored. In the recent PARAGON-HF [Prospective
Comparison of ARNI (angiotensin receptor–neprilysin inhibitor)
with ARB (angiotensin receptor blockers) Global Outcomes in
HF with Preserved Ejection Fraction], sacubitril/valsartan narrowly
missed the primary endpoint (P = 0.058) of total hospitalizations
for HF and death from cardiovascular causes among patients with
HF and an ejection fraction of 45% or higher.6
Sodium–glucose co-transporter 2 (SGLT2) inhibitors have
emerged as novel anti-hyperglycaemic agents which have shown
consistent benefit for HF hospitalizations in patients with
type 2 diabetes mellitus (T2DM), who are especially prone to
develop HFpEF.7–10 Furthermore, results from the DAPA HF trial
(Dapagliflozin in Patients with Heart Failure and Reduced Ejection
Fraction) and EMPEROR-Reduced (Empagliflozin Outcome Trial
in Patients With Chronic Heart Failure With Reduced Ejection
Fraction) showed that the risk of worsening HF or cardiovascular
mortality was significantly lower with SGLT2 inhibitors compared
with placebo by 25%, regardless of the presence or absence of
T2DM, indicating that the therapeutic role of SGLT2 inhibitors in
HF with reduced ejection fraction (HFrEF) extends to patients
beyond T2DM.10–12 Independent of their glucose-lowering action,
SGLT2 inhibitors exert broader multi-system metabolic benefits,
including reduction in cardiac inflammation and fibrosis, weight





















































. function.13,14 These effects may contribute to improving HFpEF
outcomes.
The EMPEROR program is evaluating the effects of empagliflozin
on HF in two large randomized controlled trials with one focusing
on patients with a reduced ejection fraction (EMPEROR-Reduced,
NCT03057977) and the other focusing on patients with a pre-
served ejection fraction (EMPEROR-Preserved, NCT03057951).
This report describes the baseline characteristics of the
EMPEROR-Preserved cohort and compares them with the
patients enrolled in prior HFpEF trials.6,15–18
Methods
Study design
The EMPEROR-Preserved trial is a phase III multicentre, randomized,
double-blind, parallel-group, placebo-controlled trial evaluating the
effects of empagliflozin on morbidity and mortality in patients with
established HFpEF, with or without T2DM (Figure 1). The trial is
registered as ClinicalTrials.gov Identifier: NCT03057951. The design
paper has been published in full previously and is summarized below
briefly.19
Study patients
Adults ≥18 years with chronic HF [New York Heart Association
(NYHA) class II–IV] for at least 3 months and in whom left ventric-
ular ejection fraction (LVEF) was >40% at its most recent assessment
and in whom no prior measurement of ejection fraction of ≤40%
was noted were enrolled. Eligible patients were required to have ele-
vated N-terminal pro B-type natriuretic peptide (NT-proBNP) con-
centrations (i.e. >300 pg/mL in patients without atrial fibrillation and
>900 pg/mL in patients with atrial fibrillation) and structural heart
changes (increased left atrial size or left ventricular mass) or a doc-
umented hospitalization for HF within 12 months of screening. After
a screening period of 4–28 days, patients were randomized 1:1 to
placebo or empagliflozin 10 mg/day, in addition to standard of care
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 The design of the EMPEROR-Preserved trial. CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; CV, cardiovascular;
eGFR, estimated glomerular filtration rate; HF, heart failure; HHF, hospitalization for heart failure; LVEF, left ventricular ejection fraction;
NT-proBNP, N-terminal pro B-type natriuretic peptide; NYHA, New York Heart Association; T2D, type 2 diabetes.
that is mostly driven by the management of comorbidities (e.g. coro-
nary artery disease and hypertension) and as per the discretion of
the treating physician. Randomization was done using permuted block
design with a computer pseudo-random number generator and was
stratified based on geographical region, estimated glomerular filtra-
tion rate (eGFR) and status of T2DM. The primary endpoint was the
time-to-first-event analysis of the combined risk for adjudicated car-
diovascular death and adjudicated hospitalization for HF. The trial is
event-driven and will end when 841 adjudicated primary events have
occurred.
Baseline data
All patients underwent a detailed baseline visit which included med-
ical and social history based on patient self-report and chart review.
The following variables were collected at the baseline visit: prior hos-
pitalization for HF, myocardial infarction, stroke, chronic obstructive
pulmonary disease, asthma, hypertension, dyslipidaemia, defibrillator,
pacemaker, atrial fibrillation, T2DM, chronic kidney disease, smok-
ing history and alcohol intake. All medications were also noted at
the time of baseline visit. Physical examination and laboratory data
included heart rate, systolic and diastolic blood pressure, height,
weight, complete blood count, and urine microalbumin. Twelve-lead
electrocardiogram (ECG) and health status assessment using the
23-question Kanas City Cardiomyopathy Questionnaire were also
performed.
Comparisons with other relevant trials
Baseline characteristics from EMPEROR-Preserved were compared











































.. in PARAGON-HF, TOPCAT (Treatment of Preserved Cardiac Func-
tion Heart Failure With an Aldosterone Antagonist), I-PRESERVE
(Irbesartan in Heart Failure With Preserved Ejection Fraction),
CHARM-Preserved (Candesartan in Heart Failure: Assessment of
Reduction in Mortality and Morbidity) and PEP-CHF (Perindopril in
Elderly People With Chronic Heart Failure).6,15–18 Baseline character-
istics comparing patients by region of enrolment at baseline are also
reported.
Results
Enrolment of study participants
Between March 2017 and April 2020, 11 585 patients were
screened in 23 countries, and 5988 patients were ultimately
enrolled in EMPEROR-Preserved. Six percent of the patients were
enrolled in the trial based only on HF hospitalization within the past
12 months, 77% were enrolled based on evidence for presence of
structural heart disease, while 16% had both.
Baseline demographic and clinical
characteristics
Among patients enrolled from various regions (45% Europe, 11%
Asia, 25% Latin America, 12% North America and 6% other),
the mean age was 72± 9 years, and 45% were women. Overall,
76% of the patients were white (Table 1). The median duration
of HF prior to randomization was 2.6 [interquartile range (IQR)
1.0–5.8] years. The majority of the patients had a history of
hypertension (90%), but blood pressure was 132/76 mmHg at time
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Comparison of baseline demographic and clinical characteristics of patients enrolled in EMPEROR-Preserved
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Age (years)a 72± 9 73± 8 69±10 72± 7 67±11 75 (72–79)
Women (%) 45 52 52 60 40 56
Obese (%) 45 49 55 41 38 NR
Race (%)
White 76 82 89 93 92 N/A
Black 4 2 9 2 4 N/A
Asian 14 13 1 1 2 N/A
Native American/other 6 1 <1 NR 0 N/A
NYHA class (%)
II 82 72 63 22 61 NR
III 18 27 33 77 38 NR
IV 0.3 0.6 <1 3 2 NR
Hypertension (%) 90 96 91 89 64 79
Diabetes (%) 49 43 32 27 28 21
Chronic kidney disease (%) 50 47 39 31 35 NR
Obstructive/central sleep apnoea (%) 7 / 1 NR NR NR NR NR
COPD (%) 13 14 12 NR NR NR
Current smoker (%) 7 7 10 NR 14 NR
Anaemia (%) 14 NR NR 15 27 NR
History of CAD (%) 35 43 59 13 33 NR
History of myocardial infarction (%) 29 23 26 24 44 27
History of atrial fibrillation/flutter (%) 52 52 35 29 29 NR
History of malignancy 10 NR NR NR NR NR
Stroke (%) 10 10 8 10 9 NR
Prior HF hospitalization within
12 months before visit 1 (%)
23 48 72 23 69 NR
ICD (%) 4 0.4 1 NR 0.8 NR
MAGGIC risk score 19.1± 5.6 20± 6 NR NR NR NR
Medications (%)
Diuretics 86 96 82 Loop = 83;
thiazide = 52
75 Loop = 46;
thiazide = 55
ACE inhibitors 40 40 65 26 19a –
ARBs 39 45 20 N/A N/A –
ARNI 2 – NR NR NR NR
MRA 37 24 – 15 12 NR
Beta-blockers 86 75 78 59 56 55
CCB 30 36 38 40 31 33
Nitrates 12 17 15 27 33 51
Aspirin 42 40 65 NR 58 66
Antiplatelet (except aspirin) 16 13 NR 59 5 NR
Anticoagulants 48 27 23 19 10 16
Statins 69 62 53 NR NR NR
Cardiac glycosides 9 9 NR 14 28 12
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; CAD, coronary artery disease; CCB, calcium channel
blocker; COPD, chronic obstructive pulmonary disease; HF, heart failure; ICD, implantable cardioverter defibrillator; MAGGIC, Meta-Analysis Global Group in Chronic Heart
Failure; MRA, mineralocorticoid receptor antagonist; N/A, not applicable; NR, not recorded; NYHA, New York Heart Association.
aMean± standard deviation (except for median and interquartile range for PEP-CHF).
of study enrolment. At baseline, 2163 patients (36%) had a sys-
tolic blood pressure ≥140 mmHg or a diastolic blood pressure
≥90 mmHg. Most patients had NYHA functional class II symptoms






.. chronic kidney disease defined as an eGFR <60 mL/min/1.73 m2
(50%), or a history of atrial fibrillation or atrial flutter (52%); a
large percentage were overweight or obese with a body mass
index (BMI) >30.0 kg/m2 (45%). The proportion of patients with
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Empagliflozin in HFpEF with or without diabetes 2387
anaemia was 14%. Most of the patients were on a diuretic (86%),
on renin–angiotensin–aldosterone system inhibitor therapy with
angiotensin-converting enzyme inhibitors or angiotensin receptor
blockers (78%) or sacubitril/valsartan (2%) and beta-blockers
(86%). Thirty-seven percent of the patients were on a mineralocor-
ticoid receptor antagonist (MRA) and 67% were on a loop or high
ceiling diuretic, while 21% were on thiazides or low-ceiling diuret-
ics. Twenty-three percent of patients had a prior HF hospitalization
within the past 12 months. The mean MAGGIC (Meta-Analysis
Global Group in Chronic Heart Failure) risk score for mortality
at baseline was 19.1± 5.6. Many patients had peripheral oedema
(29%), abnormal jugular venous distention (7%) and pulmonary
rales (8%) at baseline. S3 gallop was not frequently present (1%).
Comparison of baseline demographic
and clinical characteristics to prior heart
failure with preserved ejection fraction
trials
Overall, the characteristics of patients enrolled in
EMPEROR-Preserved were similar to the patients enrolled in
the PARAGON-HF trial. A larger percentage of patients were
on MRA (37% vs. 24%) and beta-blocker (86% vs. 75%) therapy
in EMPEROR-Preserved compared with PARAGON-HF. The
use of any diuretic (86% vs. 96%), history of coronary artery
disease (35% vs. 43%) and presence of NYHA class III symptoms
(18% vs. 27%) was higher in the PARAGON-HF cohort. T2DM
(49% vs. 43%) was more common in the patients enrolled in
EMPEROR-Preserved. Compared with TOPCAT, I-PRESERVE,
CHARM-Preserved and PEP-CHF, EMPEROR-Preserved study
participants had higher burden of comorbidities (particularly
regarding presence of chronic kidney disease and T2DM), but had
similar age and sex distribution. EMPEROR-Preserved (14%) and
PARAGON-HF (13%) had significantly higher enrolment of Asian
individuals than other prior HFpEF trials (Table 1). The overall
mean MAGGIC risk score at baseline in EMPEROR-Preserved
(19.1± 5.6) and PARAGON-HF (20± 6) was similar. HF signs such
as peripheral oedema, abnormal jugular venous distention and
pulmonary rales were more frequently present in PARAGON-HF
(45%, 17% and 11%, respectively) and TOPCAT (60%, 18% and
15%, respectively) compared with EMPEROR-Preserved.
Baseline laboratory, echocardiographic
and electrocardiographic characteristics
The LVEF of patients enrolled in EMPEROR-Preserved is 54± 9%
(mean± standard deviation) – 33% of patients had a baseline
LVEF 41–50%, and 782 patients (13.1%) had a baseline LVEF
41–45%. The majority (82%) of the patients had left atrial enlarge-
ment at baseline. The median (IQR) NT-proBNP concentration
was 974 (499–1730) pg/mL (Table 2). In the 5216 patients with
baseline LVEF >45%, median NT-proBNP concentration was 963
(494–1705) pg/mL. Overall, the median (IQR) eGFR was 60
(46–75) mL/min/1.73 m2. Twenty-four percent of the patients had



















































































.. with diabetes at baseline was 7.3± 1.5% [median: 6.8% (6.3–7.8%)].
Based on ECG recording at the time of screening, atrial fibrillation
or atrial flutter was present in 35% of the patients.
Comparison of baseline laboratory
and electrocardiographic characteristics
to prior heart failure with preserved
ejection fraction trials
The median NT-proBNP concentration was slightly higher while
the mean LVEF was lower in the EMPEROR-Preserved cohort com-
pared with prior HFpEF trials including PARAGON-HF (Table 2).
Presence of atrial fibrillation at screening was largely similar in all
trials except PEP-CHF (21%), in which it was markedly lower. A
higher number of patients in the EMPEROR-Preserved cohort had
eGFR <45 mL/min/1.73 m2 compared with the previous trials (24%
vs. 18%).
Baseline characteristics by region
of enrolment
Table 3 shows the baseline characteristics according to region of
enrolment. Patients enrolled in Asia had lower average BMI and
were less likely to be in NYHA class III, to have chronic obstructive
pulmonary disease or to be on angiotensin-converting enzyme
inhibitors. Patients enrolled in North America were more likely
to be obese, have obstructive sleep apnoea, anaemia, history of
coronary artery disease and malignancy. Baseline blood pressure,
heart rate, mean eGFR and LVEF were similar across the patients
enrolled in different regions.
Discussion
EMPEROR-Preserved is the first randomized controlled trial of
treatment with an SGLT2 inhibitor in HFpEF patients with and
without T2DM aiming to show the impact of this therapeutic
approach on hard outcome events. It represents the most con-
temporary cohort and largest outcomes trial for HFpEF conducted
to date with approximately 1000 more patients enrolled than in
the PARAGON-HF trial (Graphical Abstract). The baseline charac-
teristics of HFpEF patients enrolled in EMPEROR-Preserved were
generally similar to the broader population of HFpEF and prior tri-
als with some differences including higher burden of comorbidities,
lower ejection fraction, slightly higher NT-proBNP and greater use
of MRA at baseline. Similar to previous trials,6,15–18 more than 30%
of the patients had atrial fibrillation or atrial flutter at screening and
more than half had atrial fibrillation/flutter at screening or prior
history of atrial fibrillation/flutter suggesting the close relationship
between HFpEF and atrial fibrillation.
There are several interesting differences between the base-
line characteristics of EMPEROR-Preserved and recent prior
studies in HFpEF. The majority of the patients were enrolled
based on evidence of presence of structural changes in the
heart (i.e. increases in left atrial size or left ventricular mass
on echocardiography within 6 months of enrolment). Only
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Comparison of baseline physical examination, laboratory, echocardiographic and electrocardiographic
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BMI (kg/m2)a 30± 6 30± 5 32± 7 30± 5 29± 6 28 (25–30)
Atrial fibrillation/flutter (%, at screening)b 35 32 28 29 29 21
LBBB (%) 9 7 8 8 NR NR
RBBB (%) 9 NR 11 NR NR NR
LV hypertrophy (%) 10 NR 29 31 15 NR
Paced rhythm (%) 8 NR 7 NR NR NR
E/e′ ≥13 (%) 13 NR NR NR NR NR
Any LA size/volume increase at baseline (%) 82 92c NR NR NR NR
LA width≥4 cm (%) 59 NR NR NR NR NR
LA length≥5 cm (%) 21 NR NR NR NR NR
LA area≥20 cm2 (%) 23 NR NR NR NR NR
LA volume≥55 mL (%) 15 NR NR NR NR NR
LA volume index ≥34 mL/m2 (%) 20 NR NR NR NR NR
Baseline weight (kg) 82±19 NR 90± 22 NR NR NR
Baseline heart ratea 70±12 70±12 69± 10 71± 10 71±12 73 (66–82)
Baseline SBP (mmHg)a 132±16 136±15 129±14 136±15 136±18 139 (129–150)
Baseline DBP (mmHg)a 76±11 77±11 76± 11 79± 9 78± 11 80 (74–86)
Baseline NT-proBNP (pg/mL) 974 (499–1730) 885 (863–908) 950 (588–1920) – – –
LVEF (%)a 54± 9 58± 8 57± 7 59± 9 54± 9 64 (56–66)
eGFR (mL/min)a 60.6±19.8 63±19 68± 20 73± 23 NR NR
<45 23.8 18 NR NR NR NR
45 to <60 26.1 30 NR 31 NR NR
≥60 50.1 53 NR NR NR NR
Baseline haemoglobin (g/dL)a 13± 2 NR 13± 2 14 13 NR
Baseline troponin (ng/mL)a 23.7± 30 NR NR NR NR NR
Haemoglobin A1c (%)a 7.3±1.5 NR NR NR NR NR
BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; LBBB, left bundle branch block; LA, left atrial; LVEF, left ventricular ejection
fraction; NR, not recorded; NT-proBNP, N-terminal pro B-type natriuretic peptide; RBBB, right bundle branch block; SBP, systolic blood pressure.
aMean± standard deviation where available (except for median and interquartile range for PEP-CHF).
bBased on electrocardiogram.
cSite reported.
23% of the patients in the EMPEROR-Preserved cohort had
a recent HF hospitalization. This low rate was only similar to
that in I-PRESERVE.16 In comparison, in TOPCAT overall and
in CHARM-Preserved, 70% of the patients had hospitalization
for HF within the 12 months prior to enrolment.15,17 This was
somewhat lower with 50% in sites of the Americas in TOPCAT
as well as in PARAGON-HF.20,21 The relatively low rates of recent
HF hospitalization in EMPEROR-Preserved should have no major
effect on generalizability of the trial results, if not increase the gen-
eralizability slightly, as patients were enrolled based on structural
changes in the heart or elevated NT-proBNP which may be more
commonly consistent with real-world HFpEF patients.
The differences in baseline characteristics may, to some degree,
also be related to the somewhat differential requirements for
natriuretic peptide elevation in these studies, and notably different
requirements based on whether or not the patient had previously

























. patients without a prior hospitalization with HF had to have ele-
vated natriuretic peptides (B-type natriuretic peptide ≥100 pg/mL
or NT-proBNP ≥360 pg/mL).15 In PARAGON-HF, patients with-
out compared to those with a prior HF hospitalization had to
meet a higher NT-proBNP threshold level for inclusion [e.g. those
without prior HF hospitalization had to meet a >300 pg/mL limit
(>600 pg/mL if AF was present at screening), while those with a
prior HF hospitalization had to meet >200 pg/mL (>600 pg/mL,
if in AF at screening)]. In EMPEROR-Preserved, however, all
patients had to have raised NT-proBNP levels to be eligible with
NT-proBNP >300 pg/mL (or >900 pg/mL, if in AF at screening).19
The inclusion of patients with LVEF of 41–44% did not impact the
median NT-proBNP observed in the EMPEROR-Preserved cohort
(974 pg/mL for all patients vs. 963 pg/mL without the 782 patients
with LVEF <45%).
Other relevant differences in baseline characteristics are wor-
thy of discussion. I-PRESERVE, PARAGON-HF and TOPCAT
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Age (years)a 73±10 70±10 73± 8 72± 9 69±11
Women (%) 44 47 46 36 46
Obese (%) 59 44 50 9 48
Race (%)
White 86 71 99 0 48
Black 11 10 0.2 0 8
Asian 2 2 0.1 100 27
Native American/other (%) 1 17 0.7 0 17
NYHA class (%)
II 76 85 81 89 70
III 23 15 19 10 30
IV 0.7 0.3 0.2 0.4 0
Hypertension (%) 95 91 92 81 86
Diabetes (%) 51 54 47 44 52
Obstructive sleep apnoea (%) 32 2 4 5 13
COPD (%) 24 10 13 5 16
Current smoker (%) 7 5 8 10 6
Anaemia (%) 34 8 12 19 15
History of CAD (%) 46 31 34 38 29
History of myocardial infarction (%) 31 37 27 25 23
History of atrial fibrillation/flutter (%) 57 30 63 60 45
History of malignancy 23 4 11 8 12
Stroke (%) 10 9 9 16 8
Prior HF hospitalization within 12 months before visit 1 (%) 26 14 23 34 29
ICD (%) 8 2 4 2 3
Medications (%)
Non-MRA diuretics 84 74 85 67 83
ACE inhibitors 32 33 52 22 33
ARBs 34 52 31 46 34
ARNI 4 3 1 4 3
MRA 24 40 38 43 40
Beta-blockers 85 86 88 83 75
CCB 36 26 30 40 27
Nitrates 26 11 9 12 19
Aspirin 50 56 32 36 46
Anticoagulants 50 25 61 53 42
Statins 74 68 70 60 74
Digoxin 7 6 12 11 8
Baseline NT-proBNP (pg/mL)b 1043
(528–1860)




LVEF (%)a 56± 8 54± 9 53± 8 57± 9 55± 9
Baseline SBP (mmHg)a 131±17 130±16 134±15 129±16 133±17
Baseline DBP (mmHg)a 73±11 76±10 76±10 75±12 76±11
Baseline heart rate (bpm)a 69±12 69±11 71±12 72±13 71±12
BMI (kg/m2)a 32± 6 30± 6 30± 5 25± 4 31± 6
eGFR (mL/min)a 56.3±19.8 62.1± 21.4 60±18 64±19 62.5± 22.9
<45 31 23 23 18 27
45 to <60 28 23 28 27 21
≥60 41 54 49 55 52
Baseline haemoglobin (g/dL)a 13± 2 13± 2 14±1 13± 2 13± 2
Baseline troponin (ng/mL)a 29.1± 37 22.5± 27.9 22.1± 27 26.3± 38 25.5± 24.1
Haemoglobin A1c (%)a 7.4±1.6 7.6±1.7 7.0±1.2 6.9±1.1 7.6±1.8
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; CAD, coronary artery disease; CCB, calcium channel blocker; BMI, body mass
index; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HF, heart failure; ICD, implantable cardioverter defibrillator; LVEF, left
ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro B-type natriuretic peptide; NYHA, New York Heart Association; SBP, systolic blood pressure.
aMean± standard deviation.
bMedian and interquartile range.
included only those patients with HF and LVEF ≥45%, while
EMPEROR-Preserved enrolled patients with HF and LVEF >40%.
The use of an LVEF threshold of 40% explains why the ejection
fractions were lower in EMPEROR-Preserved. The use of an LVEF
threshold of 40% might allow for treatment of potentially more








. between prior standards for reduced and preserved LVEF. Fur-
thermore, the burden of comorbidities (particularly with chronic
kidney disease and T2DM) was somewhat higher in patients
enrolled in EMPEROR-Preserved and a higher number of patients
had eGFR <45 mL/min/1.73 m2. This could have been due to
the exclusion criteria cut-off set at 20 mL/min/1.73 m2 instead of
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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30 mL/min/1.73 m2 compared with other trials such as TOPCAT
and PARAGON-HF. In EMPEROR-Preserved, 310 patients had an
eGFR <30 mL/min/1.73 m2, and 1113 patients had an eGFR of
30.0 to <45 mL/min/1.73 m2. Interestingly, mean BMI was rather
similar in the trials compared here, despite noticeable differences
in BMI inclusion criteria. EMPEROR-Preserved included patients
with a BMI <45 kg/m2 at screening, whereas it was for instance
≤40 kg/m2 in PARAGON-HF.
Lastly, background therapy with MRAs and beta-blockers was
considerably higher while the use of diuretics (any) was somewhat
lower in EMPEROR-Preserved compared with PARAGON-HF
(86% vs. 96%). In comparison, use of any diuretic at baseline in
TOPCAT was 82%. Regarding MRA use, this may in part be due to
the results of the TOPCAT trial, which suggested possible benefit
in reducing first and recurrent HF hospitalizations with spirono-
lactone in HFpEF patients.15 This is important because studies
have suggested that MRAs can exert systemic effects on colla-
gen metabolism and may help to reduce pre- and afterload that
may specifically hinder or reverse myocardial, vascular and renal
fibrosis, which may have an important component in HFpEF.22,23
Consequently, EMPEROR-Preserved will be able to test the poten-
tial efficacy of empagliflozin in addition to the use of MRAs (mostly
spironolactone). Higher use of diuretics in PARAGON-HF may be
related to the protocol which mandated diuretic therapy for at least
30 days before screening.
Some limitations should be considered while interpreting base-
line data of EMPEROR-Preserved. The comparison of the severity
and overall burden of comorbidities between EMPEROR-Preserved
and prior HFpEF trials could not be done for some variables (in part
due to lack of such information from other trials).
In summary, the EMPEROR-Preserved trial is the largest clinical
trial ever conducted in patients with HFpEF to date. Compared
to other contemporary HFpEF trials, the EMPEROR-Preserved
cohort has some notable differences. These include a higher bur-
den of comorbidities, many patients with low eGFR and T2DM,
and overall these patients have a somewhat lower ejection frac-
tion, slightly higher NT-proBNP concentration and high use of
MRAs at baseline. EMPEROR-Preserved will determine whether
the SGLT2 inhibitor empagliflozin – which has previously been
shown to improve outcomes in HFrEF patients independent of
T2DM status11 – will also reduce morbidity and mortality in
patients with HFpEF. As several biomarkers of cardiac and renal
injury (including NT-proBNP, troponin T and eGFR), metabolic
markers (including uric acid, haemoglobin A1c and haemoglobin),
a large array of omics biomarkers, as well as adiposity and body
weight change will also be evaluated, the EMPEROR-Preserved trial
is also well poised to further our mechanistic understanding of the
disease and of the pathophysiologic effects of empagliflozin. Results
of the EMPEROR-Preserved trial will be available in 2021.
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